The net loss of cardiomyocytes during myocardial infarction is a key factor in the resulting remodelling and in the impairment of cardiac-pump function [1] . Prompt reperfusion of the infarctrelated coronary artery has considerably salvaged the ischaemic myocardium and limited the infarct size [2] . Nevertheless, heart failure that develops after infarction remains a leading cause of morbidity and mortality [3].
randomized controlled trial conducted by Janssens et al. [9] showed that cell transfer within 24 hrs post-AMI failed to improve left ventricular contractile function. Based on these preliminary results, the optimal time frame for cell therapy for AMI seems to be within the period from day 4 to day 7 after the infarction (Table 1) . However, the mechanism underlying time-dependent therapeutic efficacy remains unclear.
Current researches on this scientific issue tend to decipher it by time course of the production of inflammatory cytokines and growth factors after AMI, which were involved in survival and differentiation of the engrafted cells [6, 11, 12] . Experimentally, the early inflammatory process in infarcted myocardium, which might adversely affect the biological and functional behaviours of the engrafted cells, subdued at 1 week post-AMI [13] , and meanwhile some beneficial factors (e.g. vascular endothelial growth factor [VEGF] , hepatocyte growth factor [HGF] ) are at their peak concentrations [14] . In this period, the biochemical microenvironment within the ischaemically injured myocardium might be suitable for the regeneration of functional myocardium and neovascularization in the broken heart associated with cellreplacement therapy [15] [16] [17] . However, it is noteworthy that the biochemical response within the myocardium after AMI is an exceedingly complex network. Although some inflammatory factors and cytokines may benefit the engrafted cells, the majority are believed to be deleterious for survival and differentiation of the stem cells [18] . Even the same cytokines often have [24] . The cardiac remodelling process following myocardial infarction is mainly induced by myocardial fibrosis starting with massive extracellular matrix deposition, which in combination with the tissue necrosis stiffens the heart muscle. Berry et al. experimentally found that the elastic modulus for the non-infarcted myocardium of rats was about 18 kPa, whereas the 2-week infarcted myocardium is threefold stiffer than the normal myocardium (E~ 55 kPa) [25] 
Concretely, soft matrices (elastic modulus [E, a material property that describes its stiffness or elasticity] of 0.1-1.0 kPa) that mimic brain favoured differentiation of BMCs into neuronal-like cells, moderate elasticity (E~ 11 kPa) that mimics muscle-promoted myogenic differentiation, and a rigid matrix (E~ 34 kPa) that mimics collagenous bone-stimulated osteogenic differentiation [21]. That is to say, stem cells are able to feel and respond to the stiffness of their microenvironment to commit to a relevant cell phenotype. It is natural to associate these findings with the fact that the myocardium post-infarction experiences a time-dependent stiffness change from flexible to rigid. Pathologically and anatomically, the injured cardiomyocytes no longer stay intact in its early stage of infarction as tissue necrosis and inflammatory edema follow. Young scar formation begins about 1 week after the infarction. Scar maturation begins at 2 weeks and completes at 4 weeks after AMI

